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1. Introduction
In mammals, bilirubin is the most toxic metabolites that
require to undergo detoxification in the liver to prevent its
increased accumulation. Bilirubin is produced in large quantities
from the normal turnover of hemoglobin and other hemoproteins,
however during normal condition human body has evolved an
efficient detoxification mechanism to eliminate it. Bilirubin
behaves like a lipophilic compound; this imposes its insolubility
that adversely affects its excretion [1]. Glucuronidation of
bilirubin makes it soluble and renders its excretion through bile
and urine [2,3]. Bilirubin conjugation reaction with glucuronic
acid is catalyzed by Bilirubin-UDP-glucuronosyltransferase 1A1
(UGT1A1) or Bilirubin-UGT [4], one of the 19 members of the UGT
gene family [5]. UGT gene expression is regulated by an
antioxidant response element (ARE) in their promoter region
[6]. A transcription factor Nrf2, one of the members of NF-E2
family of nuclear basic leucine zipper transcription factors [7],
which binds to ARE region and regulates UGTs transcription. In
Nrf2ÿ/ÿ mice UGTs expression is greatly impaired in liver and
gastrointestinal tract [8,9] that leads to accumulation of bilirubin
[10]. Since persistent hyperbilirubinemia may cause serious
health problems including death, glucuronidation of bilirubin by
UGT1A1 is a vital requirement. Therefore, a search for UGT1A1
inducer becomes extremely important.
At one time only choice to deal with the accumulation of
insoluble bilirubin was to treat with phenobarbital barbiturate.
Earlier reports with phenobarbital have demonstrated that it
stimulates UGT1A1 activity thereby enhanced rapid glucuronida-
tion reaction thus converting bilirubin to its readily excretable
glucuronidated form [11]. Phenobarbital has considerable side
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Accumulation of bilirubin, primarily because of its insolubility, has been found to be associated with liver
diseases including jaundice. Free bilirubin is insoluble; its glucuronidation by bilirubin-UGT enzyme
(UGT1A1) makes it soluble and eliminates it through urine and faeces. Taking CCl4 induced rat liver
dysfunction model, we demonstrated that suppression of UGT1A1 activity in rat liver increased serum
bilirubin level which could be reversed by carlinoside (Cln), a flavone glycoside. Although Cln is a flavone
compound, it escaped self-glucuronidation in the intestine and readily absorbed. Kinetic study of
microsomal UGT1A1 from HepG2 cells suggested that Cln enhanced enzyme activity by increasing Vmax
without altering Km. This altered Vmaxwas found to be due to UGT1A1 overexpression by Cln which was
observed in both HepG2 and rat primary hepatocytes. Since Nrf2 is the transcription factor of UGT1A1,
we examined whether Cln effect on UGT1A1 overexpression is mediated through Nrf2. In Nrf2 knock-out
cells, Cln could not elevate UGT1A1 activity indicating Nrf2 to be its target. Cln significantly increased
Nrf2 gene expression in HepG2 cells which was subsequently localized in nuclear region. Results from
ChIP assay showed that Cln markedly augmented Nrf2 binding to UGT1A1 promoter that consequently
enhanced reporter activity. Our findings therefore show that Cln upregulated Nrf2 gene expression,
increased its nuclear translocation and stimulated UGT1A1 promoter activity. Total outcome of these
events brought about a significant increase of bilirubin glucuronidation. Cln therefore could be a worthy
choice to intervene hyperbilirubinemia due to liver dysfunction.
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effects, better alternative to it includes, dietary flavones which do
not have problem of side effects and are considered suitable to
treat hyperbilirubinemia [12,13]. One of the important flavonoids
belonging to this class is chrysin (5,7-dihydroxyflavone); chrysin
has been shown to induce UGT1A1 expression in liver cells and
greatly enhanced bilirubin glucuronidation in HepG2 cells [14,15].
Moreover, there are convincing evidences on chrysin’s ability to
induce UGT1A1 expression in tissue culture models [16]. However,
transgenic mice that expresses human UGT1 locus, when orally
treated with chrysin showed no effect on liver UGT1A1 expression
because of the problem of bioavailability [17,18]. Majority of the
beneficial flavonoids are found to be the substrates of the intestinal
UGTs as in the case of chrysin and that created problems for their
bioavailability [13,17]. This has restricted their use to augment
important phase 2 antioxidant enzyme families like UGTs. Hence,
there is a crucial need to have a safe, effective and bioavailable
compound that can deal hyperbilirubinemia problem.
In this report we describe that Carlinoside (Cln), a dietary
flavone glycan, readily eliminates insoluble bilirubin through the
process of glucuronidation by augmenting UGT1A1 activity in CCl4
induced hyperbilirubinemic rat model. By taking human hepatoma
cell line HepG2 and rat primary hepatocyte (PH) we have shown
that Cln overexpresses UGT1A1 by inducing Nrf2 gene, this causes
a significant increase in its activity thereby converting insoluble
bilirubin to its soluble form. Cln therefore could be an attractive
drug candidate to deal hyperbilirubinemia.
2. Materials and methods
2.1. Chemicals and reagents
Uridine 50-diphosphoglucuronic acid triammonium salt, hemin,
isocitrate dehydrogenase and PCR primers for UGT1A1, Nrf2 and
HO-1 were purchased from Sigma Chemical Co. (St Louis, MO,
USA). [3H]-Leucine (specific activity 1000 Ci/mmol) was obtained
from GE Healthcare Biosciences Ltd., Kowloon, Hong Kong. Assay
kits for bilirubin, GPT and GOT were procured from Span
Diagnostics, India. Carbon tetrachloride (CCl4), n-Butyl acetate,
Ethyl anthranilate, Pentane 2-one, isocitrate and NADPH were
purchased from E. Merck, Darmstadt, Germany. All tissue culture
materials were obtained from Gibco BRL, Life Technologies Inc.,
Gaithersburg, USA. Primary antibodies for anti-UGT1A1 (anti-
goat), anti-Nrf2 (anti-rabbit), anti-Keap1 (anti-goat), anti-HO-1
(anti-goat) and alkaline phosphatase conjugated anti-goat, anti-
rabbit secondary antibodies were purchased from Santa Cruz
Biotechnology Inc., CA, USA. Control (Cat. No. sc-37007) and Nrf2
siRNA (Cat. No. sc-37030) were also purchased from Santa Cruz
Biotechnology Inc., CA, USA. All other chemicals were purchased
from Sigma Chemical Co. (St Louis, MO, USA).
2.2. Isolation of carlinoside from Cajanus cajan leaf
The fresh mature leaves of C. cajan were pulverized in a motor
driven grinder with methanol-water (MeOH:H2O, 1:1) followed by
our earlier report [19] and then fractionated through Diaion HP20
and ODS column chromatography. The eluent was loaded into an
analytical HPLC amide column which gave a single peak in
analytical Symmetry C18 column with water:methanol (55:45) as
solvent and detection at 254 nm. The peak was identified as
Carlinoside, by 1D, 2D NMR and Q-TOF-MS and making a similar
derivative (Fig. 1).
2.3. Animals and treatment
Adult male albino rats of the Sprague-Dawley strain weighing
180–220 g were maintained under standard laboratory conditions
in clean polypropylene cages (2–3 animals/cage) with food and
water made available ad libitum, under 12 h light/dark cycle at
25  2 8C. Animals were acclimated about one week prior to use. For
analysis of Cln effect on CCl4 induced liver damage, 5 rats per group
were administered CCl4 at 0.25 ml/kg bw with corn oil (1:1, v/v) i.p.
every alternate day for 28 days and observation was continued till 42
days without further administration of CCl4. At day 28, Cln was
administered at a dose of 25 mg/kg bw to one group of CCl4 treated
rats through oral gavage. On termination of the experiments rats were
sacrificed and blood samples were collected for estimation of serum
bilirubin and liver function marker enzymes, GPT and GOT. Liver was
perfused with ice-cold 1.15% KCl and immediately frozen on dry ice
and stored at ÿ80 8C for further studies. Liver tissues were also kept
for histological analysis. To determine bioavailability, 5 rats were
administered with a single oral dose of 50 mg/kg Cln. Blood was
collected and liver was taken out after 4 h to determine the amount of
Cln through HPLC analysis. All experiments were performed
following the guidelines prescribed by the Animal Ethics Committee
at Visva-Bharati University, Santiniketan, India.
2.4. Cell culture and treatment
The human hepatoma HepG2 cell line was a kind gift from
National Centre for Cell Science, Pune, India and Dr. Partha P.
Banerjee, Georgetown University Medical Centre, Washington DC,
USA. HepG2 cells were cultured in MEM (minimum essential
medium) containing Earle’s salts and non-essential amino acids
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate,
10% fetal calf serum, penicillin (100 U/ml) and streptomycin
(100 mg/ml) in a humidified 95% O2/5% CO2 atmosphere at 37 8C
[20]. For treatments, CCl4 was dissolved in 10% DMSO and used at
concentrations of 6 mM in HepG2 incubations along with 10 mM
Fig. 1. Flow chart of carlinoside (Cln) isolation. Methanol extract of C. cajan leaves
was chromatographed through HP-20 Diaion and ODS column followed by HPLC in
Symmetry C-18 column which was eluted with water:methanol (55:45) solvent.
Structure of Cln is provided in the lower panel.
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Cln for 24 h or as per the design of the experiment. In all the cases
Cln was used 1 h prior to CCl4 treatment.
Primary culture of hepatocytes was performed by isolating the
cells from male Sprague-Dawley rat liver using collagenase perfusion
as described previously [21]. The initial hepatocyte viability
measured by trypan blue exclusion was always >90%. Cells were
cultured in MEM containing 10% FBS and treated with 10 mM Cln.
Control and treated cells were lysed in lysis buffer (1% NP-40, 20 mM
HEPES (pH 7.4), 2 mM EDTA, 100 mM NaF, 10 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 mg/ml leupeptin,
1 mg/ml aprotinin, 1 mg/ml pepstatin and 1 mM PMSF) and
centrifuged for 10 min at 10,000 g. Nuclear extract was prepared
following a previously described method [22]. Amount of proteins in
the samples were determined by the method of Lowry et al. [23].
2.5. Measurement of bilirubin-UGT activity
Microsomes were prepared from rat liver and HepG2 cells
following a method described previously [24]. Microsomal protein
was resuspended in MOPS buffer, pH 7.2 (20 mM MOPS, 100 mM
KCl, 20 mM NaCl, 3 mM MgCl2) at a concentration of 10–20 mg
protein/ml and frozen under liquid N2 until required. Bilirubin-
UGT activity was therefore determined using microsomal protein
by the method described by Seppen et al. [25], with modifications.
Briefly, bilirubin dissolved in 0.2 N NaOH and bound to BSA (final
concentration: 0.34 mM bilirubin, 8 mg/ml BSA) was incubated in
a mixture containing 20 mM Tris–Cl (pH 7.6), 5 mM MgCl2, 5 mM
saccharolactone, 0.1% Triton X-100 and 1 mg of microsomal
protein/ml in a final volume of 200 ml. The reaction was initiated
by addition of UDP-glucuronic acid with 5 mM final concentration
and incubated for 30 min at 37 8C. The reaction was stopped by
addition of 300 ml glycine–HCl buffer (0.4 M HCl, pH adjusted to
2.7 with glycine) and the samples were diazotized and extracted
following the method of Heirwegh et al. [26]. 1.5 volumes of diazo-
reagent (0.1 ml of ethyl anthranilate, 0.3 ml of 70 mM NaNO2, and
0.1 ml 88 mM ammonium sulfamate in 10 ml of 150 mM HCl) was
added to the mixture for 30 min at room temperature. The diazo
reaction was stopped by adding 1 volume of freshly prepared
ascorbic acid solution (570 mM). The bile pigment formed was
extracted by vigorous shaking with 3 volumes of methylpropylk-
etone:n-butyl-1-acetate (17:3, v/v) and the absorbance of the
organic phases were measured at 530 nm. The amount of bilirubin
glucuronides was determined from the E530 value, E530 = 44,
400 Mÿ1 cmÿ1.
2.6. Measurement of heme oxygenase activity
Heme oxygenase (HO) activity was determined according to a
previously described method [24] with little modification. Briefly,
the reaction mixture (6.0 ml) contained microsomes (10 mg
protein); 105,000  g supernatant (6 mg of protein); 17 mM
hemin; 180 mM NADPH; 0.85 mM isocitrate, 0.2 mg/ml of
isocitrate dehydrogenase and 0.1 M potassium phosphate buffer,
pH – 7.4. The reaction mixture was divided equally and added to
two cuvettes, incubated for 5 min at 37 8C, reaction was initiated
by adding NADPH (in 0.4 mM NaHCO3 final concentration) to the
sample cuvette and equal amount of NaHCO3 in the reference
cuvette. HO activity was estimated on the basis of bilirubin
formation at 468 nm and HO activity was calculated from the
millimolar extinction coefficient, E468 = 57 mM
ÿ1.
2.7. Electrophoresis and immunoblotting
60 mg protein from the lysates of control and treated HepG2 cells
or rat PH was resolved on 10% SDS-PAGE and transferred to PVDF
membranes (Millipore, Bedford, MA) with the help of semi-dry trans
blot apparatus (Bio-Rad Trans-Blot1 SD Cell, USA) using transfer
buffer (25 mM Tris, 193 mM glycine, 20% methanol, pH 8.5). The
membranes were first incubated with primary antibodies of
UGT1A1 (goat polyclonal, 1:1000), Nrf2 (rabbit polyclonal,
1:1000), Keap1 (goat polyclonal, 1:1000) and HO-1 (goat polyclonal,
1:1000) followed by corresponding ALP-conjugated secondary
antibodies at 1:1000 dilution using SNAP i.d. (Millipore, Bedford,
MA). The protein bands were detected by using 5-bromro 4-chloro
3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT).
2.8. Reverse transcription PCR and real-time quantitative PCR
Total RNA was extracted from control and treated HepG2 cells or
rat PH using the TRI Reagent. RT-PCR was performed using First
Strand cDNA Synthesis Kit, Fermentas Life Sciences, Revert AidTM,
Hanover, MD, USA, following a previous description from this
laboratory [20,27]. Alteration in UGT1A1 and Nrf2 gene expression
was observed using their specific primers (human UGT1A1 forward:
50-AACAAGGAGCTCATGGCCTCC-30; reverse: 50-GTTCGCAAGATTC-
GATGGTCG-30; human Nrf2 forward: 50-TGCCCCTGGAAGTGT-
CAAACA-30; reverse: 50-CAACAGGGAGGTTAATGATTT-30 [28];
human HO-1 forward: 50-AACTTTCAGAAGGGCCAGGT-30; reverse:
50-CTGGGCTCTCCTTGTTGC-30; rat UGT1A1 forward 50-CCACC-
CAATGCCCTGCT-30, reverse: 50-CACCATTGGAACCCCATTGC-30; rat
HO-1 forward: 50-CACCAGCCACACAGCACTAC-30, reverse: 50-CACC-
CACCCCTCAAAAGACA-30; gapdh forward: 50-GCCATCAAC-
GACCCCTTC-30; reverse: 50-AGCCCCAGCCTTCTCCA-30). Alteration
in gene expression was confirmed further by real-time PCR using
Power SYBR green PCR master mix (Applied Biosystems, CA, USA).
3 mg of total RNA from each sample was reverse transcribed and PCR
was performed with gene specific primers in a total volume of 20 ml
in the following real-time PCR conditions: initial activation step
(95 8C, 15 min), cycling step (denaturation 95 8C, 30 s, annealing at
55 8C, 30 s, and finally extension for 72 8C, 30 s, 40 cycles) followed by
their melt curve analysis (55–60 8C, 15 s, 40 cycles). A house keeping
gene, gapdh, was simultaneously amplified in separate reactions and
acted as an internal control. The Ct value was corrected using
corresponding Ct value of gapdh controls. Data from 3 determina-
tions (means  SEM) are expressed as relative expression level.
2.9. Nrf2 siRNA interference assay
HepG2 cells (1  106 cell/well) were transfected with
80 pmoles of control or Nrf2 siRNA (Santa Cruz Biotechnology
Inc., CA, USA) using lipofectamineTM2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. After 48 h of
transfection, cells were incubated with 10 mM of Cln. At the end of
incubation cells were harvested and analyzed for Western blot and
RT/qPCR analysis.
2.10. [3H]-Leucine incorporation study
HepG2 cells were serum starved in Kreb’s Ringer Phosphate
(KRP) buffer supplemented with 0.2% bovine serum albumin. To
determine the amount of UGT1A1 protein synthesis, untransfected
or Nrf2 siRNA transfected HepG2 cells were incubated without or
with Cln in the presence of 10 mCi/ml [3H]-leucine for 0–12 h time
period. Cells were lysed and supernatant was pulled down by using
anti-UGT1A1 antibody following our previous description [20].
Radioactive count was measured in liquid scintillation counter
(Perkin Elmer, Tri-Carb 2800TR).
2.11. Chromatin Immunoprecipitation (ChIP) assay
ChIP assay was performed according to our previous description
[29] using a ChIP assay kit (Upstate, Temecula, CA, USA). Briefly, 70%
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confluent HepG2 cells (1  106 cells/well) were incubated with
10 mM Cln for 8 h, and then fixed in 1% formaldehyde for 10 min at
37 8C. Cells were lysed, nuclei isolated by centrifugation and
chromatin was sheared using a sonicator. Chromatin was immu-
noprecipitated with 2 mg of anti-Nrf2 or control IgG antibody (Santa
Cruz Biotechnology Inc., CA, USA). The primers for human UGT1A1-
ARE promoter [30] sequence (UGT1A1 forward: 50-
GTACTTGCTGTGGTACCTCCAGAAT-30 and reverse: 50-
GGCGCCTTTGCTCCTGCTCGAGGTTC-30) was used for amplification
of immunoprecipitated DNA. The PCR products were resolved on
ethidium bromide stained 1.5% agarose gel and image was captured
by Bio-Rad gel documentation system using Image Lab software.
2.12. Reporter assay
UGT1A1 promoter-luciferase reporter construct was the kind
gift provided by Prof. Chantal Guillemette of Laval University,
Quebec, Canada and pNFE2-luc construct containing the 930 bp
promoter region (Chr. 12q13:52980872-52981801) of the human
Nrf2 gene (Gene ID: 4778) was procured from Switch Gear
Genomics, Menlo Park, CA, USA. HepG2 cells were seeded in a 24
well plate (1  105 cells/well) and were grown overnight to 50%
confluence one day before transfection. Cells were then transfected
with 750 ng of the reporter constructs along with 5 ng of Renilla
luciferase plasmid using LipofactamineTM 2000. Following 48 h of
transfection, cells were treated with Cln (10 mM). Luciferase
activity was determined using Promega Dual-Luciferase Reporter
Assay System.
2.13. Immunofluorescence assay
Control or treated HepG2 cells were incubated with anti-rabbit
Nrf2 antibody (1:100) for 2 h followed by immunostaining with
FITC-conjugated goat anti-rabbit antibody (1:1000) for 1 h. Nucleus
was stained with propidium iodide (Invitrogen, Carlsbad, CA, USA)
following manufacturer instructions. Coverslips were mounted in
glycerol/PBS and images were captured in fluorescence microscope
(Carl Zeiss, USA) using Jenoptik software (ProgRes1CapturePro 2.7).
2.14. Statistical analysis
Data were analyzed by one-way analysis of variance (ANOVA)
where the F value indicated significance, means were compared by
a post hoc multiple range test. All values were means  SEM.
3. Results
3.1. Cln reverses CCl4 induced liver damage by stimulating bilirubin-
UGT activity
CCl4 is a well-established hepatotoxin and used in animal
models to induce liver damage [31], for this reason we have
Fig. 2. Cln waived CCl4 induced accumulation of bilirubin and stimulates UGT1A1 activity in the liver. (A) Rats were administered CCl4 for 28 days and then treated with Cln by
oral gavage up to 42 days. Blood was collected from control and treated rats on the days mentioned and serum samples were subjected for the estimation of total bilirubin. (B)
Conjugated and unconjugated bilirubin was determined in serum of 42 days treated rats to see the extent of bilirubin glucuronidation. (C) Bilirubin-UGT activity was
measured in microsomal samples from treated and untreated rat liver after 42 days of treatment. (D) Rats were treated orally with 25 mg/kg bw Cln and induction of UGT1A1
activity was determined using liver microsomal preparation on the days mentioned. Each experiment was performed in triplicate. Values are expressed as mean  SEM
(n = 6). *p < 0.05 and **p < 0.001 (vs. control), #p < 0.001 (vs. CCl4).
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selected CCl4 for our present study. Chronic administration of CCl4
for 28 days resulted considerable damage to the liver. Liver
histology due to CCl4 treatment showed sinusoidal congestion,
infiltration of inflammatory cells, perinuclear vacuolization in the
hepatocytes and disintegrated hepatocytes, all these indicate
serious damage to the liver. This was also reflected from the sharp
increase of serum GPT and GOT activity (Fig. S1A–C). Administra-
tion of Cln to one group of CCl4 treated rats on day 28 considerably
improved liver histology as observed at day 42 and serum GPT and
GOT activity within a week or two. These results suggest that Cln
treatment effectively waived adverse effects of CCl4 on liver.
Chronic treatment of this dose of CCl4 elevated serum bilirubin to a
very high level till day 42 in a linear fashion while administration
of Cln with one group of CCl4 treated rats at day 28 drastically
reduced serum bilirubin level on day 42 suggesting that Cln is
efficiently removing bilirubin and most likely through solubiliza-
tion (Fig. 2A). Since results with Cln implicate greater solubiliza-
tion of bilirubin we determined unconjugated and conjugated
levels of serum bilirubin with CCl4 or Cln treated rat. CCl4 greatly
increased unconjugated bilirubin which was remarkably dropped
in the presence of Cln (p < 0.001) at 42 days of treatment (Fig. 2B).
This effect of Cln was obtained within two weeks of administration
because it was administered on day 28 on treated rats and effect
was observed at 42 day.
Such a marked alteration from insoluble to soluble form of
bilirubin due to Cln suggests a massive increase in glucuronidation
reaction catalyzed by bilirubin-UGT enzyme (UGT1A1). We
therefore determined Cln effect on UGT1A1 (bilirubin-UGT)
enzyme activity with liver microsomal preparation from CCl4
treated rats. CCl4 significantly reduced UGT1A1 activity (p < 0.05)
while oral administration of Cln at day 28 greatly enhanced its
activity when observed at 42 day (Fig. 2C). Such a robust increase in
UGT1A1 activity by Cln in CCl4 treated rats prompted us to
investigate further to observe whether Cln alone could augment
UGT1A1 activity. Fig. 2D demonstrates that 14 days Cln treatment
stimulated UGT1A1 activity to more than 2 fold as compared to
control. This appears to be intriguing but question remained on the
mechanism through which Cln manifested UGT1A1 upregulation.
This question we addressed through in vitro experiments with
hepatocytes; prior to that we examined Cln bioavailability, as
flavone compounds have a history of poor absorption through the
intestine.
To observe its absorption through gastrointestinal tract, Cln was
administered through oral route at a dose of 50 mg/kg bw. Fig. 3
shows that considerable amount of Cln could be detected in the
serum at 3 h of oral administration and an appreciable quantity of
it could be detected in the liver extract at 4 h. This shows that
bioavailability would not be a problem with Cln as faced by other
bioactive flavone compounds [18,32].
3.2. Stimulation of bilirubin UGT activity by Cln is due to its
overexpression
To understand the mechanism of Cln regulation of UGT1A1
activity, we performed experiments with human liver cell line,
HepG2 and rat primary hepatocyte (PH). UGT1A1 activity was
determined by using microsomal preparation from HepG2 cells
incubated with CCl4, Cln or tBHQ. CCl4 inhibition of UGT1A1
activity was not only suppressed by Cln, it further enhanced the
activity significantly (p < 0.001) (Fig. 4A). Similar trend of result
was obtained with PH cells (Fig. S2A), indicating that Cln does not
contradict CCl4 but its induction for UGT1A1 expression overcomes
CCl4 inhibitory effect. We used tBHQ because of its known UGT
inducing activity and compared with Cln to evaluate Cln efficiency
for inducing UGT activity in HepG2 cells. It would be evident from
Fig. 4A that Cln and tBHQ both effected about 1.5 fold increase in
UGT1A1 activity over the control, Cln effect was more prominent
and significantly higher than tBHQ (p < 0.05). A kinetic study on
UGT1A1 demonstrated that Km remained unaltered by CCl4 or Cln,
whereas Vmax was decreased by CCl4 (p < 0.01) and considerably
increased by Cln (p < 0.001) over the control (Fig. 4B). These results
led us to presume that Cln opposing effect of CCl4 could be
mediated through UGT1A1 expression. To examine this, we
determined UGT1A1 protein expression.
Fig. 5A demonstrates that Cln overexpresses UGT1A1 protein
while CCl4 downregulates the same. Cln could effectively
suppressed CCl4 inhibitory effect on UGT1A1 expression. We
performed immunoblot with HepG2 and PH cells incubated with
CCl4 or Cln or both. There was a significant increase of UGT1A1
expression from 5 mM to 10 mM, whereas 20 mM of Cln did not
produce considerable higher effect over 10 mM (Fig. 5B). PH cells
showed similar trend (Fig. S2B). HepG2 cells incubated with Cln
Fig. 3. Cln efficiently absorbed in the serum and liver on oral administration. Rats
(n = 5) were administered with a single oral dose of 50 mg/kg bw Cln. Serum was
collected and liver was taken out to analyze the presence of Cln through HPLC
against a standard Cln peak. Figures are representative of one of three independent
experiments.
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for different time periods (from 0 to 24 h) and subsequent
immunoblotting demonstrated a time dependent increase in the
UGT1A1 expression (Fig. 5C). To examine whether this enhanced
UGT1A1 protein expression by Cln was due to its induction of
UGT1A1 gene, we performed RT-PCR and qPCR of UGT1A1 from
Cln incubated HepG2 and PH cells. Cln greatly enhanced UGT1A1
gene expression (p < 0.01) in both the cases (Fig. 5D).
3.3. Cln augmentory effect on UGT1A1 is mediated through Nrf2
Overexpression of UGT1A1 may occur through Ah receptor or
Nrf2. Since majority of reports indicated Nrf2 as the regulator of
UGT1A1 gene, we checked this possibility through siRNA driven
Nrf2 knockout HepG2 cells. Cln could not elevate UGT1A1 protein
and gene expression in these cells while in untransfected or mock
Fig. 4. Cln induces UGT activity by increasing Vmax. (A) HepG2 cells were treated with or without CCl4 (6 mM) or Cln (10 mM) or tBHQ (10 mM) for 24 h. Microsomal samples
were prepared to determine UGT activity towards bilirubin. (B) Kinetic analysis of bilirubin-UGT activity was performed. Microsomal samples from HepG2 cells were
prepared from the untreated (&) or CCl4 (6 mM, *) or Cln (10 mM, !) or CCl4 + Cln (^) treated incubations and used with varied concentrations of bilirubin (0–20 mM) in the
presence of 5 mM UDPGA for each reaction. On termination of reactions amount of glucuronidated bilirubin was plotted using double reciprocal plot to analyze Km and Vmax
values. Each value is the mean  SEM of three independent experiments, *p < 0.05 and **p < 0.001 (vs. control), #p < 0.001 (vs. CCl4).
Fig. 5. Dose and time dependent increase of UGT1A1 expression by Cln. (A) HepG2 cells were incubated with or without CCl4 (6 mM) or Cln (10 mM) or CCl4 + Cln for 24 h.
Microsomal sample was subjected to immunoblot analysis using anti-UGT1A1 antibody. (B) HepG2 cells were treated with or without Cln at different doses (5, 10 and 20 mM)
for 24 h. Microsomal sample was immunoblotted with anti-UGT1A1 antibody. (C) UGT1A1 expression was observed for indicated time periods. b-Actin served as loading
control. (D) HepG2 cells and primary hepatocytes (PH) were treated with or without Cln (10 mM) for 24 h. On termination of incubation, cells were lysed and total RNA was
extracted for RT-PCR and real time PCR analysis of UGT1A1. GAPDH served as internal control. Figures are representative of one of three independent experiments.
Mean  SEM were calculated from 5 individual experiments. *p < 0.001 (vs. control).
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siRNA transfected cells Cln effected massive increase of UGT1A1
expression (Fig. 6A). These results have following indications, (i)
Cln stimulation of UGT1A1 expression is mediated through Nrf2,
(ii) Cln has no direct effect on UGT1A1 expression and (iii) Cln
effect possibly does not include Ah receptor pathway. Further work
by monitoring UGT1A1 protein synthesis in Cln incubated HepG2
cells was studied in the presence of [3H]-leucine and at each time
point, cells from control or Cln incubations were lysed and
immunoprecipitated using anti-UGT1A1 antibody attached to
sepharose 4B beads. The precipitated protein was monitored for
[3H]-leucine incorporation in a time dependent manner as
indicated. A linear increase in the Cln induced UGT1A1 protein
synthesis could be observed till 12 h of Cln incubation which was
considerably decreased in Nrf2 knockout cells (Fig. 6B). This shows
that UGT1A1 protein synthesis is dependent on Nrf2. This was
further evident from the increased bilirubin glucuronidation due to
Cln which was sufficiently depressed in Nrf2 knockout cells
(Fig. 6C).
3.4. Overexpression of Nrf2 by Cln is associated with increased
UGT1A1 promoter activation
To investigate Cln effect on Nrf2, we determined Nrf2 protein
and gene expression in Cln incubated HepG2 cells and found Cln
significantly enhanced its protein and gene expression. As
anticipated, this effect of Cln was not seen in Nrf2 knockout cells
(Fig. 7A). To provide additional evidence of Cln effect on Nrf2, we
performed Nrf2 reporter assay and found that promoter activity
was considerably increased (p < 0.001) due to Cln as compared to
the control cells (Fig. 7B). Time dependent increase in the Cln
induced Nrf2 protein expression and its distribution to the
cytosolic or nuclear region was also analyzed in HepG2 cells. It
would be evident from Fig. 7C that Nrf2 protein could be detected
in the nuclear fraction at 2 h which was greatly increased at 8 h.
Same results were obtained with immunofluorescence detection;
massive accumulation of Nrf2 protein could be visualized in the
nuclear region of Cln treated cells at 8 h whereas it was restricted
to cytoplasm in control cells. Similar results were obtained with
tBHQ (Fig. 7D). Excess of Nrf2 accumulation in the nuclear region
could be due to enhanced Nrf2 expression and may also be for
Keap1 degradation which stabilizes Nrf2 in the cytoplasm. It could
be seen from Fig. 7E that Keap1 reduction in cytosol occurred
between 6 and 8 h which corresponded with the higher Nrf2 in
nuclear region at 8 h suggesting that enhanced Nrf2 nuclear
localization is also associated with Keap1 degradation in response
to Cln. Since silencing of Nrf2 blocked Cln induced UGT1A1
expression and activity, Nrf2 appears to be the target of Cln.
However, heme oxygenase-1 (HO-1), another important Nrf2
target gene, is involved in the production of bilirubin from heme.
Thus induction of HO-1 by Nrf2 may results in increased turn over
of bilirubin, whereas Cln was found to reduce bilirubin through
UGT1A1. To look into this confusion, rats were treated without
(control) or with Cln and sacrificed on day 7 and 14. The results of
this experiment showed an increase in HO-1 gene expression but
Fig. 6. Cln overexpressed UGT1A1 through Nrf2. (A) HepG2 cells were transfected with mock or Nrf2 siRNA (Nrf2 KO) followed by incubation with or without 10 mM Cln for
24 h. Microsomal sample was subjected to immunoblot analysis using anti-UGT1A1 antibody. b-Actin served as loading control. Total RNA was extracted from the above
incubations followed by RT-PCR and Real-time PCR (qPCR) analysis using UGT1A1 gene specific primers where GAPDH served as an internal control. (B) HepG2 cells were
incubated for different time periods (0–24 h) as indicated without or with 10 mM Cln following their transfection with control or Nrf2 siRNA (Nrf2 KO) in the presence of
10 mCi of [3H]-leucine. Cells were lysed and immunoprecipitated with anti-UGT1A1 antibody and processed for radioactive counting. (C) siRNA transfected HepG2 cells (Nrf2
KO) were incubated with or without 10 mM Cln for 24 h. Conjugation of bilirubin was studied using a saturated concentration of bilirubin (120 mM) and amount of
glucuronide formed was determined in the medium by HPLC. Mean  SEM was calculated from 5 individual experiments. *p < 0.001 (vs. control); #p < 0.01 (vs. Cln).
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surprisingly Western blot analysis exhibited a significant decrease
in HO-1 protein expression in response to Cln (Fig. 8A). The same
was observed in in vitro experiments with HepG2 cells (Fig. 8B).
However, Cln significantly reduced heme oxygenase activity both
in in vivo and in vitro experiments (Fig. 8A and B); this may be a
reflection of reduced protein expression in response to Cln. Taken
together, Cln enhanced UGT1A1 gene and protein expression while
it increased HO-1 gene expression but decreased protein expres-
sion along with the inhibition of enzyme activity.
To demonstrate that Nrf2 binding to UGT1A1 promoter effected
greater expression of UGT1A1, we performed chromatin immu-
noprecipitation (ChIP) assay with control and Cln treated HepG2
cells. Chromatin preparation from these cells was immunopreci-
pitated with anti-Nrf2 antibody. UGT1A1 promoter region was
therefore amplified using oligonucleotide primers from the DNA
recovered from immunoprecipitated complex of both control and
treated cells. Nrf2 binding to UGT1A1 promoter region was
significantly enhanced in Cln incubated cells (Fig. 9 A), suggesting
greater promoter activity. To examine promoter activity, UGT1A1
promoter-luciferase reporter construct was transfected to HepG2
cells followed by incubation with Cln. There was more than two
fold increase in UGT1A1 luciferase activity by Cln as compared to
control which was not observed in Nrf2 knockout cells (Fig. 9B).
The results so far obtained suggest that Nrf2-UGT1A1 pathway is
greatly stimulated due to overexpression of both Nrf2 and UGT1A1,
Cln triggers Nrf2 expression which in turn increased UGT1A1 gene
and protein expression resulting greater conversion of insoluble to
soluble form of bilirubin. This was checked in HepG2 cells loaded
Fig. 7. Cln induces Nrf2 expression and its nuclear translocation. (A) siRNA transfected HepG2 cells (Nrf2 KO) were incubated with or without Cln for 6 h. On termination of
incubations cells were lysed and immunoblotted with anti Nrf2 antibody. b actin served as an internal control. RNA extracted from the cells was subjected to RT-PCR and qPCR
analysis using Nrf2 gene specific primers taking gapdh as an internal control. (B) pNrf2-luc reporter plasmid transfected HepG2 cells were co-transfected with or without
mock or Nrf2 si-RNA (Nrf2 KO). After transfection HepG2 cells were incubated without or with 10 mM Cln. On termination of incubation reporter activity was measured by
using luciferase assay system. (C) HepG2 cells were incubated for different time periods (0–8 h) as indicated without or with 10 mM Cln. Cytosolic and nuclear extracts were
prepared and immunoblotted with anti-Nrf2 antibody. b actin served as an internal control. (D) HepG2 cells were incubated without or with Cln or tBHQ, on termination of
incubation cells were fixed and permeabilized. Cells were then incubated with anti-Nrf2 antibody for 4 h followed by FITC conjugated goat anti-rabbit secondary antibody for
2 h. PI was used to stain the nucleus. Figures are representative of one of three independent experiments (magnification 400). (E) HepG2 cells were incubated without or
with 10 mM Cln for 0–8 h as indicated and lysates from each incubation was immunoblotted with anti-Keap1 antibody. b actin served as an internal control. Each value is the
mean  SEM of 5 individual experiments. *p < 0.001 (vs. control); #p < 0.01 (vs. Cln).
R. Kundu et al. / Biochemical Pharmacology 82 (2011) 1186–1197 1193
with bilirubin, thoroughly washed and then incubated without or
with Cln or tBHQ for 24 h. On termination of incubation,
conjugated bilirubin secreted into the medium was estimated.
Fig. 9C shows that conjugated bilirubin was significantly higher in
Cln incubated cells (p < 0.01) indicating physiological relevance of
Cln induced Nrf2 upregulation. In this case also, Cln demonstrated
significantly greater effect (p < 0.05) than tBHQ.
4. Discussion
UDP glucuronosyltransferase 1 (UGT1A1) is one of the nine
members of UGT1 sub-family encoded on UGT1 locus of
chromosome 2 in human [5]. This enzyme is also known as
bilirubin UGT as it catalyzes the solubilization of insoluble
bilirubin through glucuronidation [2–4]. Bilirubin is highly
toxic; its accumulation in different tissues and organs produces
serious health problems including death. Glucuronic acid
conjugation is the primary route of elimination for bilirubin
where UGT1A1 serves as the major isoform of UGT1A sub-family
responsible for the glucuronidation of endogenous bilirubin [2–
4]. UGT1A1, therefore, plays a vital role by eliminating bilirubin.
To deal with excess accumulation of bilirubin that occurs during
impairment of liver and jaundice, there is a need to get an
effective inducer of this enzyme. Several chemical compounds
are reported to induce UGT1A1 but most of them are potentially
harmful [33,34].
We initiated this investigation with in vivo experiments since
majority of the dietary flavonoids demonstrate effective glucur-
onidation in in vitro cell culture experiments but their promise
fail because of bioavailabilty problem. We have isolated Carlino-
side (Cln), a flavone glycoside from C. cajan leaf, it is a dietary
flavone as the pulse of this plant is a popular food and contains
sufficient amount of Cln. It demonstrates a strong capability in
eliminating bilirubin by converting insoluble bilirubin to soluble
form through glucuronidation. CCl4 is a well-established liver
toxicant used in animal models and leads to higher accumulation
of bilirubin. It was demonstrated in some recent reports that CCl4
causes suppression of glucuronidation activity of UGTs in the
liver and leads to impairment of disposition kinetics of
therapeutic agents through excretion [35,36]. Moreover chronic
administration of CCl4 has been reported to rupture erythrocytes
membrane and thus release heme in excess amount which is
converted to bilirubin [37]. We have observed that chronic
administration of CCl4 elevated serum bilirubin level with a
marked increase of unconjugated form by affecting impairment
of UGT1A1 activity. Interestingly, when rats have already in
hyperbilirubinemic condition at 28 day of CCl4 treatment, oral
administration of Cln radically improved the situation within a
week or two. This suggests Cln’s great potentiality in dealing
hyperbilirubinemia
One of the well studied flavonoid in relation to the induction of
UGT1A1 is chrysin, also available from dietary component and at
Fig. 8. Cln induces HO-1 gene transcription but reduces its protein expression and activity. (A) Rats were administered without or with Cln at a dose of 25 mg/kg bw and
sacrificed on the days as indicated. Total RNA was prepared from the liver samples and subjected to RT-PCR analysis using HO-1 gene specific primers where gapdh served as
loading control. Homogenates were prepared from the liver samples and immunoblotted with anti-HO-1 antibody. b actin served as an internal control. Portions of the liver
homogenates were subjected to microsomal preparation to determine heme oxygenase activity expressed in terms of bilirubin formation. (B) HepG2 cells were incubated
without or with 10 mM Cln for 6 h. On termination of incubations cells were lysed and total RNA was prepared for RT-PCR and cell lysate was immunoblotted using gene
specific primers and antibody respectively. Each value is the mean  SEM (n = 5) of 3 individual experiments. #p < 0.02, *p < 0.001 (vs. control).
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one time it promised for the amelioration of liver disease. Chrysin
induced UGT1A1 expression and activity has been reported in
primary hepatocytes [14], the human liver cell line, HepG2 [14,15]
and human intestinal cell line, Caco2 [16]. Chrysin therefore has
shown a great potentiality to deal hyperbilirubinemia. However,
bioavailability of chrysin has become a problem because of its
rapid glucuronidation in the intestine followed by its elimination
[17,18]. In contrast, oral administration of Cln to rat did not
showed problem for its bioavailability, a considerable amount of it
could be detected in the serum and liver. Presence of glycan
moieties in this flavone probably attributed a protection against
intestinal glucuronidation. This presumption may be the fact
because two important dietary isoflavones, aglycone daidzein and
its glycosylated sister molecule, daidzin showed a significant
difference in their bioavailability. Absorption of daidzin through
the intestine is far more successful than daidzein [38].
Results from in vivo experiments with CCl4 induced hyperbilir-
ubinemic rats also provided an indication that Cln bioavailability
would not be a problem. This encouraged us to study the
underlying mechanism of Cln induced stimulation of UGT1A1
activity. To investigate this, we used human liver cell line, HepG2
and rat primary hepatocyte (PH). Since passaging of cell line
sometime alters cellular response, PH represented natural or
normal cellular characteristics. Both of these cell types responded
similarly to Cln in relation to enhanced UGT1A1 activity indicating
this to be an inherent property of Cln. Kinetic studies on HepG2
microsomal preparation furnished little important information.
UGT1A1 activity in control and treated cells taking bilirubin as
substrate exhibited no alteration of Km due to Cln or CCl4 treatment
and comparable to some current reports [39,40]; while Cln
dramatically increased Vmax (111.2  1.3 pmol/min/mg protein), it
falls significantly due to CCl4 and revive considerably by Cln. Increase
of Vmax by Cln without altering Km indicates a likely increase of
UGT1A1 expression as observed with Chrysin [14–16]. In fact, Cln
strikingly enhanced gene and protein expression of UGT1A1 in both
HepG2 and PH cells. Flavone compounds have been reported to
increase expression and activity of UGT1A1 in intestinal and liver cell
lines [14–16,18]. Unfortunately, bioavailability problem deter their
future drug promise. In that respect Cln has promise, as its availability
in serum and liver on oral administration suggests its escape from
intestinal glucuronidation.
Another attractive aspect of our findings is the Cln induction on
Nrf2; it does not have a direct effect on UGT1A1 expression since
Nrf2 knockout cells do not respond to Cln. This transcription factor
which binds to ARE region expresses number of important genes
including the UGTs that regulate detoxification of several
endobiotic and xenobiotic compounds, dietary, therapeutics
and some environmental substances [41,42]. In normal condition
Nrf2 remain bounds to a protein Keap1 in the cytosolic region. On
induction, Nrf2 is released from Keap1 and then translocated to
the nuclear region that leads to transcription of its target genes
[42,43]. We have observed that Cln overexpresses Nrf2 along with
its increased translocation to nuclear region of HepG2 cells. It’s
binding to the ARE region of UGT1A1 promoter has been
significantly augmented by Cln that consequently enhances
UGT1A1 promoter activity. There may be a confusion regarding
Cln effect on bilirubin reduction as HO-1 is a target gene for Nrf2
[44,45], therefore Cln induced overexpression of Nrf2 would likely
increase HO-1 expression. HO-1 converts heme to biliverdin and
biliverdin reductase catalyzes formation of bilirubin from
biliverdin. We have found that Cln increased HO-1 gene
expression but reduced protein expression and that adversely
affects its activity. However, why enhanced gene expression is not
reflected into protein expression is not clear to us. It may be due to
the inhibition of translation or increased proteasomal degrada-
tion of HO-1. In both in vivo and in vitro experiments Cln inhibited
heme oxygenase activity and that would expectedly not permit
for excess bilirubin production. However, to understand the
underlying mechanism for differential effect of Cln on HO-1
requires further investigation.
Fig. 9. Cln enhanced Nrf2 binding to the UGT1A1 promoter. (A) HepG2 cells were incubated without or with 10 mM Cln for 24 h and fixed with 1% formaldehyde. Chromatin
was immunoprecipitated with anti-Nrf2 antibody and control IgG-Nrf2. Nrf2 binding to UGT1A1 promoter was determined by PCR with UGT1A1 ARE specific primers. The
same primers were also used to amplify UGT1A1 ARE regions before immunoprecipitation with Nrf2 antibody to show 1% input DNA. (B) pUGT1A1-luc reporter plasmid
transfected HepG2 cells were co-transfected with or without mock or Nrf2 siRNA. After transfection cells were incubated without or with 10 mM Cln. On termination of
incubation reporter activity was determined by using luciferase assay system. (C) HepG2 cells were pre-incubated for 1 h with a saturated concentration of bilirubin
(120 mM). The cells were thoroughly washed and then treated with or without 10 mM Cln or tBHQ for 24 h. Conjugation of bilirubin was studied by determining the amount of
glucuronide formed in the medium by HPLC. Mean  SEM was calculated from 3 individual experiments. *p < 0.001 (vs. control); #p < 0.001 (vs. Cln).
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However, several problems have to be solved prior to make Cln
as drug for hyperbilirubinemia. It requires to be determined the
equivalent amount of Cln for treating hyperbilirubinemic patients,
precise amount of Cln requires to be absorbed through the gut on
oral administration and to study the mechanism of its elimination
from the body. One of the favorable points for Cln is that it may be
administered with specific diet; such a possibility requires to be
explored. In conclusion, it may be stated that Cln greatly stimulates
UGT1A1 activity and expression through the induction of Nrf2
gene and therefore bears a promise to deal hyperbilirubinemia. It’s
a dietary flavone glycan profusely available from plant source and
it successfully qualified the critical test for bioavailability which is
a crucial limitation for bioactive dietary flavones. At present we
really have a conspicuous dearth of non-toxic chemical com-
pounds to convert free insoluble bilirubin to its conjugated
solubilized form as that would ameliorate the problem of
hyperbilirubinemia. On this background Cln may serve an
attractive choice.
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